Darwin Global Management »

Tourmaline Bio shares owned by Darwin Global Management

Quarter-by-quarter ownership of Tourmaline Bio (TRML) shares owned by Darwin Global Management from 13F filings

Historical chart of Darwin Global Management investment in Tourmaline Bio

Tip: Access up to 7 years of quarterly data

All positions including Tourmaline Bio held by Darwin Global Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Tourmaline Bio by Darwin Global Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $11M 465k 22.90

More positions owned by Darwin Global Management

Vaxcyte (PCVX)
Nuvalent Inc-a (NUVL)
Keros Therapeutics (KROS)
Biohaven (BHVN)
Alpine Immune Sciences (ALPN)
Beam Therapeutics (BEAM)
Apogee Therapeutics (APGE)
Xencor (XNCR)
Spyre Therapeutics Com New (SYRE)
Elevation Oncology (ELEV)
Tourmaline Bio (TRML)
Merck & Co (MRK)

View all positions for Darwin Global Management

Top funds holding Tourmaline Bio

Blue Owl Capital Holdings
Cormorant Asset Management
Jennison Associates
QVT Financial
Vanguard Group
Braidwell
venBio Select Advisor
Nantahala Capital Management
Qiming U.S. Ventures Management
Vivo Capital
BlackRock
Darwin Global Management
Eventide Asset Management
Velan Capital Investment Management
Artal Group

View all funds holding Tourmaline Bio